# EDGAR Filing Document

**Accession Number:** 0001870404
**File Stem:** 0001213900-25-050055
**Filing Date:** 2025-6
**Character Count:** 41344
**Document Hash:** eb3a507d41556f729de0d191cac8811b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-050055.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001213900-25-050055

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250530

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CERO THERAPEUTICS HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001870404
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 871088814
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40877
- **FILM NUMBER:** 251015273

**BUSINESS ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **STREET 2:** SUITE 230
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-407-2376

**MAIL ADDRESS:**
- **STREET 1:** 201 HASKINS WAY
- **STREET 2:** SUITE 230
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHOENIX BIOTECH ACQUISITION CORP.
- **DATE OF NAME CHANGE:** 20210630

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 30, 2025**

**CERo Therapeutics Holdings, Inc.**

**(Exact name of registrant as** **specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40877** | **81-4182129** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(Commission File Number)** | **(I.R.S. Employer<br> Identification Number)** |

---

---

| | |
|:---|:---|
| **201 Haskins Way, Suite 230, South San Francisco, CA** | **94080** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (650) 407-2376**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common stock, par value $0.0001 per share** | **CERO** | **Nasdaq Capital Market** |
| **Warrants, each whole warrant exercisable for one share of common stock** | **CEROW** | **Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Employment Agreement of Current CEO*

 

On May 30, 2025, CERo Therapeutics Holdings, Inc. (the "Company"), entered into a new employment agreement with Chris Ehrlich (the "Ehrlich Employment Agreement"), under which the Company agreed to employ Mr. Ehrlich as the Company's Chief Executive Officer as of and from June 4, 2025. The agreement replaces and supersedes that certain Consulting Agreement, dated October 1, 2024, between the Company and Mr. Ehrlich, which was terminated in connection with the entry into the Ehrlich Employment Agreement. The Company determined to enter into the Ehrlich Employment Agreement commensurate with the expansion of the services provided by Mr. Ehrlich to the Company to a full-time basis. Pursuant to the Ehrlich Employment Agreement, Mr. Ehrlich is entitled to a base salary at a rate of $480,000 per annum effective June 4, 2025, prorated for any partial years of employment (the "Ehrlich Base Salary").

Pursuant to the Ehrlich Employment Agreement, Mr. Ehrlich is also eligible to earn a one time performance bonus, which will be 50% of the Ehrlich Base Salary, less applicable withholdings. Mr. Ehrlich's performance bonus will be based on the achievement of performance objectives set forth in the Ehrich Employment Agreement, the satisfaction of which shall be determined by the Company's Board of Directors (the "Board"), subject to Mr. Ehrlich's continued employment with the Company through the date that such bonus is paid, except that in the event of a Change of Control (as defined in the Ehrlich Employment Agreement) Mr. Ehrlich will be entitled to receive payment of his full performance bonus. The Ehrlich Employment Agreement also provides that Mr. Ehrlich is eligible to participate in the benefit plans of the Company, if any, in accordance with the terms of such plans in effect from time to time, including equity awards pursuant to the Company's 2024 Stock Option and Grant Plan, as amended from time to time (the "Plan"). In addition, Mr. Ehrlich will be entitled to receive a monthly contribution of up to $1,850 from the Company toward his healthcare premiums. In connection with entry into the Ehrlich Employment Agreement, Mr. Ehrlich has received certain equity awards under the Plan, the amount of such awards, vesting schedule and performance criterial are as set forth in the Ehrlich Employment Agreement.

The Ehrlich Employment Agreement is for no specific period of time and either Mr. Ehrlich or the Company may terminate the employment at any time and for any reason or no reason, with or without cause, and with or without notice.

 

*Employment Agreement of Current CFO*

On May 30, 2025, the Company entered into a new employment agreement with Andrew Albert Kucharchuk (the "Kucharchuk Employment Agreement"), under which the Company agreed to employ Mr. Kucharchuk as the Company's Chief Financial Officer as of and from June 4, 2025. The agreement replaces and supersedes that certain Consulting Agreement, dated October 1, 2024, between the Company and Mr. Kucharchuk, which was terminated in connection with the entry into the Kucharchuk Employment Agreement. The Company determined to enter into the Kucharchuk Employment Agreement commensurate with the expansion of the services provided by Mr. Kucharchuk to the Company to a full-time basis. Pursuant to the Kucharchuk Employment Agreement, Mr. Kucharchuk is entitled to a base salary at a rate of $300,000 per annum effective June 4, 2025, prorated for any partial years of employment (the "Kucharchuk Base Salary").

Pursuant to the Kucharchuk Employment Agreement, Mr. Kucharchuk is also eligible to earn a one time performance bonus, which will be 30% of the Kucharchuk Base Salary, less applicable withholdings. Mr. Kucharchuk's performance bonus will be based on the achievement of performance objectives determined by the Board, subject to Mr. Kucharchuk's continued employment with the Company through the date that such bonus is paid. The Kucharchuk Employment Agreement also provides that Mr. Kucharchuk is eligible to participate in the benefit plans of the Company, if any, in accordance with the terms of such plans in effect from time to time, including equity awards pursuant to the Plan. In addition, Mr. Kucharchuk will be entitled to receive a monthly contribution of up to $1,750 from the Company toward his healthcare premiums. In connection with entry into the Kucharchuk Employment Agreement, Mr. Kucharchuk has received certain equity awards under the Plan, the amount of such awards, vesting schedule and performance criteria are as set forth in the Kucharchuk Employment Agreement.

The Kucharchuk Employment Agreement is for no specific period of time and either Mr. Kucharchuk or the Company may terminate the employment at any time and for any reason or no reason, with or without cause, and with or without notice.

The foregoing summaries of each of the Ehrlich Employment Agreement and the Kucharchuk Employment Agreement contained in this Item 5.02 do not purport to be complete and are subject to, and qualified in their entirety by, the full text of the Ehrlich Employment Agreement and the Kucharchuk Employment Agreement, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**.

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1\*+ | [Employment Agreement by and between CERo Therapeutics Holdings, Inc., and Chris Ehrlich, dated May 30, 2025](ea024419501ex10-1_cero.htm) |
| 10.2\*+ | [Employment Agreement by and between CERo Therapeutics Holdings, Inc., and Andrew Albert Kucharchuk, dated May 30, 2025](ea024419501ex10-2_cero.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Filed herewith. <br> + Indicates management contract or compensatory plan.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 2, 2025 | cERO THERAPEUTICS HOLDINGS, Inc. | cERO THERAPEUTICS HOLDINGS, Inc. |
|  | By: | */s/ Chris Ehrlich* |
|  | Name: | Chris Ehrlich |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**OFFER LETTER**

May 30, 2025

Chris Ehrlich

Re: Offer of Employment

Dear Chris:

CERo Therapeutics Holdings, Inc. (the "Company") is pleased to offer you employment on the following terms:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Start Date**. Provided that you satisfy the conditions described in this letter agreement, your first day of employment with the Company will be June 4, 2025, or another date mutually agreed upon in writing between you and the Company. The actual day you begin employment will be referred to as the "Start Date."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Position**. Your initial title will be Chief Executive Officer, and you will initially report to the Company's Board of Directors. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Location**. Your principal place of employment will be the Company's office located in San Francisco, California. However, you are permitted to work remotely from your home office, subject to the Company's remote work policies as may be in effect from time to time. Notwithstanding the foregoing, you may be required to attend in-person meetings or work from the Company's San Francisco office on an as-needed basis, as determined by the Company in its reasonable discretion. While working remotely, you agree to only work from locations that allow you proper internet access to be able to do your job remotely.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Base Compensation**. As an exempt employee, beginning on the Start Date, the Company will pay you a base salary at the rate of $480,000.00 per year, prorated for any partial years of employment, payable in accordance with the Company's standard payroll schedule and subject to applicable deductions and withholdings. You will be paid your salary in regular installments regardless of the number of hours you work per workweek, and you will not be eligible for overtime pay.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Performance Bonus**. You are eligible to earn a one time performance bonus. Your target performance bonus will be 50% of your base salary, less applicable withholdings. Your performance bonus will be based on the achievement of performance objectives determined by the Company, which will include: (i) the Company's successful completion of capital raising activities resulting in at least $10 million in new financing since October 1, 2024, which, for the avoidance of doubt, has already been achieved; (ii) the dosing of three patients who meet all study inclusion and exclusion criteria; and (iii) the hiring of a new Chief Executive Officer. Unless otherwise provided in <u>Section 6</u> below, eligibility for any bonus is contingent upon your continued employment with the Company through the date the bonus is paid. Nothing in this offer letter requires the Company to pay a performance bonus in any particular year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Equity**. You were granted an option to purchase 238,971 shares of the Company's Common Stock (the "Option") on March 4, 2025 (the "Grant Date"), at an exercise price of $1.43 per share. The Option will be subject to the terms and conditions applicable to options granted under the stock option plan in effect at the time of the grant and the applicable stock option agreement (the "Equity Documents"). You will vest in fifty percent (50%) of the Option shares in nine (9) equal monthly installments, with one-ninth (1/9<sup>th</sup>) of the Option shares vesting on each monthly anniversary of the Grant Date, such that fifty percent (50%) of the Option shares shall be fully vested upon your completion of nine (9) months of continuous service following the Grant Date (the "Time-Based Equity Awards"). The remaining 50% of the Option shares shall vest in three (3) separate tranches, each subject to the achievement of a specific performance milestone (collectively, the "Performance-Based Equity Awards"), as follows: (i) one-third (1/3rd) of the remaining fifty percent (50%) shall vest upon the Company successfully raising capital of at least $10 million since October 1, 2024 (the "**First Milestone**") which, for the avoidance of doubt, has already been achieved; (ii) one-third (1/3rd) of the remaining fifty percent (50%) shall vest upon the Company successfully completing the dosing of three patients pursuant to its ongoing clinical trials (the "**Second Milestone**"); and (iii) one-third (1/3rd) of the remaining fifty percent (50%) shall vest upon the Company's hiring of a new Chief Executive Officer (the "**Third Milestone**").

Notwithstanding the foregoing, in the event the Company achieves the Third Milestone and, as a result, you are removed from your position as Chief Executive Officer prior to the full vesting of your Time-Based Equity Awards, all then-unvested shares subject to such Time-Based Equity Awards shall accelerate and vest in full as of the date the Third Milestone is achieved. For the avoidance of doubt, if your removal as CEO following the achievement of the Third Milestone occurs prior to the Company's achievement of the Second Milestone, you shall remain eligible to vest in the Performance-Based Equity Award upon, and subject to, the Company's subsequent achievement of the Second Milestone.

In the event of a Change of Control (as defined below), (i) all unvested shares subject to both the Time-Based Equity Awards and the Performance-Based Equity Awards shall immediately vest in full as of the date of the Change of Control, and (ii) you shall be entitled to receive payment of your full performance bonus.

The amounts payable pursuant to this section are intended, and shall be interpreted, to: (x) comply with Section 409A of the Internal Revenue Code and the Treasury Regulations and other guidance promulgated thereunder; or (y) be exempt from Code Section 409A as a "short term deferral," within the meaning of Treas. Reg. Section 1.409A-1(b)(4), or as "separation pay," within the meaning of Treas. Reg. Section 1.409A-1(b)(9). In all events, this letter agreement shall be interpreted and administered consistent with such intent. If the amounts payable pursuant to this section are to be paid in two or more installments, each installment shall be treated as a separate payment for purposes of Code Section 409A.

"**Change of Control**" or "**Change in Control**" means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:

&nbsp;&nbsp;&nbsp;&nbsp;(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company's then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the
Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof
or any other Exchange Act Person that acquires the Company's securities in a transaction or series of related transactions the primary
purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of
Ownership held by any Exchange Act Person (the "Subject Person") exceeds the designated percentage threshold of the outstanding
voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding,
provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities
by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming
the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the
Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;

&nbsp;&nbsp;&nbsp;&nbsp;(ii) there is consummated a merger, consolidation or similar transaction
involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction,
the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities
representing more than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar
transaction or (B) more than 50% of the combined outstanding voting power of the parent of the Acquiring Entity in such merger, consolidation
or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of
the Company immediately prior to such transaction;

&nbsp;&nbsp;&nbsp;&nbsp;(iii) there is consummated a sale, lease, exclusive license or
other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease,
license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity,
more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially
the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license
or other disposition; or

&nbsp;&nbsp;&nbsp;&nbsp;(iv) individuals who, on the date the Plan is adopted by the Board,
are members of the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the members of
the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or
recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of the
Plan, be considered as a member of the Incumbent Board.

Any capitalized term used but not otherwise defined herein shall have the meaning set forth in the Company's 2024 Equity Incentive Plan (the "Plan").

In addition, the Company shall grant to you an additional option award of 185,529 shares of the Company's Common Stock (the "Second Option") on May 30, 2025 (the "Second Option Grant Date"), to begin vesting on June 4, 2025 (the "Vesting Commencement Date"). The exercise price per share of the Second Option will be determined by the Board of Directors when the Second Option is granted. The Second Option will be subject to the terms and conditions applicable to options granted under the stock option plan in effect at the time of the grant and the applicable stock option agreement (the "Equity Documents"). You will vest in one-third (1/3<sup>rd</sup>) of the Second Option shares in six (6) equal monthly installments, with one-sixth (1/6th) of the Second Option shares vesting on each monthly anniversary of the Vesting Commencement Date, such that one-third (1/3<sup>rd</sup>) of the Second Option shares shall be fully vested upon your completion of six (6) months of continuous service following the Vesting Commencement Date. The remaining two-thirds (2/3<sup>rd</sup>) of the Second Option shares shall vest in two (2) separate tranches, each subject to the achievement of a specific performance milestone, as follows: (i) one-half (1/2th) of the remaining two-thirds (2/3<sup>rd</sup>) shall vest upon the Company successfully raising capital of at least $10 million following the Second Option Grant Date, subject to your continuous service as of the vesting date, and (ii) one-half (1/2th) of the remaining two-thirds (2/3rd) shall vest upon the dosing of three patients who meet all study inclusion and exclusion criteria.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **Employee Benefits**. As a regular, full-time employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits, in accordance with the applicable benefit plans. The Company will contribute up to $1,850 per month toward your healthcare premiums.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Employee Confidential Information and Inventions Assignment Agreement**. Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company's standard Employee Confidential Information and Inventions Assignment Agreement, which includes, among other terms, provisions regarding your assignment of patent rights to inventions made during your employment at the Company and your non-disclosure of the Company's proprietary information. A copy of this agreement is enclosed with this letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **Employment Relationship**. Employment with the Company is for no specific period of time. Your employment with the Company will be "at will," meaning that either you or the Company may terminate your employment at any time and for any reason or no reason, with or without cause, and with or without notice. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, supervisor, compensation, and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the "at will" nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you). If you are enrolled in direct deposit at the time of the termination of your employment, by signing this offer letter, you consent to having your final paycheck paid to you via direct deposit. You can change this election via a written notice to the Company's payroll function.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **Tax Matters**. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **Entire Agreement**. This letter agreement and the Employee Confidential Information and Inventions Assignment Agreement contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company (other than you).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. **<u>No Conflicting Obligations.</u>** By executing this letter, you represent and warrant that your performance under this letter does not and will not breach any agreement you have entered into, or will enter into, with any other party. You must disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. In addition, you agree that you will not bring any third-party confidential information to the Company, including that of any former employer, and that you will not, in any way, use any such information in performing your duties for the Company. It is the Company's understanding that any such agreements will not prevent you from performing the duties of your position, and you represent that such is the case.

By signing and accepting this offer, you represent and warrant that: (i) you are not subject to any pre-existing contractual or other legal obligation with any person, company or business enterprise which may be an impediment to, or a conflict of interest with, your employment with the Company, or your providing services to the Company as its employee; (ii) you do not have and shall not bring onto the Company's premises, or use in the course of your employment with the Company, any confidential or proprietary information of another person, company or business enterprise to whom you previously provided services; and (iii) you will not, at any time during your employment with the Company, breach any obligation or agreement that you have entered into with any third party, including your former employers. You agree not to enter into any written or oral agreement that conflicts with this letter.

Notwithstanding the foregoing, the Company agrees that your current roles as Chief Executive Officer of Launch One Ac. Co. and as Principal of Ehrlich Bioventures shall not be deemed to constitute a conflicting obligation or a violation of this Section 12.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. **Conditions of Offer**. As with all employees, the Company's offer of employment to you is also conditioned on your submission of satisfactory proof of your identity and your legal authorization to work in the United States and, if requested, your completion of a standard background check to the satisfaction of the Company. This offer is also conditioned on your signing and returning the Employee Confidential Information and Inventions Assignment Agreement on or before the Start Date.

We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing and returning a copy of this letter. This offer, if not accepted, will expire at the close of business on June 4, 2025.

If you have any questions, please contact us.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| CERo Therapeutics Holdings, Inc. | CERo Therapeutics Holdings, Inc. |
| /s/ Andrew Kucharchuk | /s/ Andrew Kucharchuk |
| Name: | Andrew Kucharchuk |
| Title: | Chief Financial Officer |

---

I have read and accept this employment offer:

---

| |
|:---|
| /s/ Chris Ehlich |
| Signature |
| Chris Ehrlich |
| Print Name |
| May 30, 2025 |
| Date |

---

Attachments(s): Employee Confidential Information and Inventions Assignment Agreement

## Exhibit 10.2

**Exhibit 10.2**

**OFFER LETTER**

May 30, 2025

Andrew Albert Kucharchuk

549 Millgate Pl

Baton Rouge, LA 70808

Re: Offer of Employment

Dear Andrew:

CERo Therapeutics Holdings, Inc. (the "Company") is pleased to offer you employment on the following terms:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Start Date**. Provided that you satisfy the conditions described in this letter agreement, your first day of employment with the Company will be June 4, 2025, or another date mutually agreed upon in writing between you and the Company. The actual day you begin employment will be referred to as the "Start Date."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Position**. Your initial title will be Chief Financial Officer, and you will initially report to the Company's Chief Executive Officer. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Location**. This is a remote job. We understand you will be working remotely from Louisiana. If you decide to work remotely from a different state, you must obtain the Company's written permission prior to working from that location. While working remotely, you agree to only work from locations that allow you proper internet access to be able to do your job remotely.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Base Compensation**. As an exempt employee, beginning on the Start Date, the Company will pay you a base salary at the rate of $300,000.00 per year, prorated for any partial years of employment (beginning October 1<sup>st</sup> 2024), payable in accordance with the Company's standard payroll schedule and subject to applicable deductions and withholdings. You will be paid your salary in regular installments regardless of the number of hours you work per workweek, and you will not be eligible for overtime pay.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Performance Bonus**. You will be eligible to earn a one-time performance bonus. Your initial target performance bonus will be 30% of your base salary, less applicable withholdings. To earn the performance bonus, (i) the Company and you must achieve applicable performance metrics, to be established and determined by the Company in its sole discretion, and (ii) you must remain employed by the Company on the date the bonus is paid (which will be no later than March 15th of the calendar year following the calendar year to which the bonus pertains).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Equity**. Subject to the approval of the Company's Board of Directors, you will be granted an option to purchase 152,500 shares of the Company's Common Stock (the "Option") on May 30, 2025 (the "Grant Date"), to begin vesting on June 4, 2025 (the "Vesting Commencement Date"). The exercise price per share of the Option will be determined by the Board of Directors when the Option is granted. The Option will be subject to the terms and conditions applicable to options granted under the stock option plan in effect at the time of the grant and the applicable stock option agreement (the "Equity Documents"). You will vest in the Option shares in twenty-four (24) equal monthly installments, such that all of the Option shares shall be fully vested upon your completion of twenty-four (24) months of continuous service following the Vesting Commencement Date. The vesting of the Option shares will be subject to acceleration if you are terminated without Cause (as defined under the Plan) or resign for Good Reason (as defined below) within twelve (12) months after a Change of Control (as defined under the Plan).

"**Good Reason**" means that you have complied with the Good Reason Process (defined below) following the occurrence of any of the following events: (i) a material diminution in your responsibilities, authority or duties; (ii) a material diminution in your base salary except for across-the-board salary reductions based on the Company's financial performance similarly affecting all or substantially all similarly situated employees; or (iii) the Company shall have required that you relocate your principal work location to any place which is more than fifty (50) miles from your principal place of work.

"**Good Reason Process**" means that (i) you reasonably determine in good faith that a "Good Reason" condition has occurred; (ii) you notify the Company in writing of the occurrence of the Good Reason condition within sixty (60) days of the occurrence of such condition; (iii) you cooperate in good faith with the Company's efforts, for a period not less than thirty (30) days following such notice (the "Cure Period"), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within sixty (60) days after the end of the Cure Period. For the avoidance of doubt, if the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **Employee Benefits**. As a regular, full-time employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits, in accordance with the applicable benefit plans. The Company will contribute up to $1,750 per month toward your healthcare premiums.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Employee Confidential Information and Inventions Assignment Agreement**. Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company's standard Employee Confidential Information and Inventions Assignment Agreement, which includes, among other terms, provisions regarding your assignment of patent rights to inventions made during your employment at the Company and your non-disclosure of the Company's proprietary information. A copy of this agreement is enclosed with this letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **Employment Relationship**. Employment with the Company is for no specific period of time. Your employment with the Company will be "at will," meaning that either you or the Company may terminate your employment at any time and for any reason or no reason, with or without cause, and with or without notice. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, supervisor, compensation, and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the "at will" nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you). If you are enrolled in direct deposit at the time of the termination of your employment, by signing this offer letter, you consent to having your final paycheck paid to you via direct deposit. You can change this election via a written notice to the Company's payroll function.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **Tax Matters**. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **Entire Agreement**. This letter agreement and the Employee Confidential Information and Inventions Assignment Agreement contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company (other than you).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. **No Conflicting Obligations.** By executing this letter, you represent and warrant that your performance under this letter does not and will not breach any agreement you have entered into, or will enter into, with any other party. You must disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. In addition, you agree that you will not bring any third-party confidential information to the Company, including that of any former employer, and that you will not, in any way, use any such information in performing your duties for the Company. It is the Company's understanding that any such agreements will not prevent you from performing the duties of your position, and you represent that such is the case.

By signing and accepting this offer, you represent and warrant that: (i) you are not subject to any pre-existing contractual or other legal obligation with any person, company or business enterprise which may be an impediment to, or a conflict of interest with, your employment with the Company, or your providing services to the Company as its employee; (ii) you do not have and shall not bring onto the Company's premises, or use in the course of your employment with the Company, any confidential or proprietary information of another person, company or business enterprise to whom you previously provided services; and (iii) you will not, at any time during your employment with the Company, breach any obligation or agreement that you have entered into with any third party, including your former employers. You agree not to enter into any written or oral agreement that conflicts with this letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. **Conditions of Offer**. As with all employees, the Company's offer of employment to you is also conditioned on your submission of satisfactory proof of your identity and your legal authorization to work in the United States and, if requested, your completion of a standard background check to the satisfaction of the Company. This offer is also conditioned on your signing and returning the Employee Confidential Information and Inventions Assignment Agreement on or before the Start Date.

We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing and returning a copy of this letter. This offer, if not accepted, will expire at the close of business on June 4, 2025.

If you have any questions, please contact us.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| CERo Therapeutics Holdings, Inc. | CERo Therapeutics Holdings, Inc. |
| /s/ Chris Ehrlich | /s/ Chris Ehrlich |
| Name: | Chris Ehrlich |
| Title: | Chief Executive Officer |

---

I have read and accept this employment offer:

---

| |
|:---|
| /s/ Andrew Kucharchuk |
| Signature |
| /s/ Andrew Kucharchuk |
| Print Name |
| May 30, 2025 |
| Date |

---

Attachments(s): Employee Confidential Information and Inventions Assignment Agreement